• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在管理癌症时考虑肾脏风险。

Considering renal risk while managing cancer.

作者信息

Shahinian Vahakn B, Bahl Amit, Niepel Daniela, Lorusso Vito

机构信息

Department of Internal Medicine, Kidney Epidemiology and Cost Center, University of Michigan, Ann Arbor, MI, USA.

Bristol Haematology and Oncology Centre, University Hospitals Bristol, Bristol, UK.

出版信息

Cancer Manag Res. 2017 May 16;9:167-178. doi: 10.2147/CMAR.S125864. eCollection 2017.

DOI:10.2147/CMAR.S125864
PMID:28553142
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5439998/
Abstract

Renal function is an important consideration in the management of patients with advanced cancer. There is a reciprocal relationship between cancer and the kidney: chronic kidney disease can increase the risk of developing cancer, and patients with cancer often experience renal impairment owing to age, disease-related factors and nephrotoxic treatments. As therapies for cancer continue to improve, patients are living longer with their disease, potentially extending the period over which they are susceptible to long-term complications. Furthermore, secondary symptoms, such as bone metastases or infections, may arise that will require treatment. Certain treatments, including chemotherapy, antibiotics and some bone-targeted agents, are nephrotoxic and may require dose modifications or interruptions to prevent renal injury. Nephrologists should play a key role in the identification and management of renal impairment in patients with cancer. Furthermore, they may be able to provide advice on protecting the kidneys in instances where nephrotoxic agents require dose reductions or interruptions, and when novel therapies or combinations are used. Collaboration between oncologists and nephrologists is important to optimal patient management. This article reviews the relationship between cancer and kidney disease and examines the treatments that may impact kidney function. Considerations for monitoring renal function are also discussed.

摘要

在晚期癌症患者的管理中,肾功能是一个重要的考量因素。癌症与肾脏之间存在着相互关系:慢性肾脏病会增加患癌风险,而癌症患者常因年龄、疾病相关因素及肾毒性治疗而出现肾功能损害。随着癌症治疗方法不断改进,患者带病生存的时间更长,这可能会延长他们易发生长期并发症的时间段。此外,可能会出现如骨转移或感染等继发症状,需要进行治疗。某些治疗方法,包括化疗、抗生素和一些骨靶向药物,具有肾毒性,可能需要调整剂量或中断治疗以预防肾损伤。肾病学家在识别和管理癌症患者的肾功能损害方面应发挥关键作用。此外,在肾毒性药物需要减少剂量或中断治疗以及使用新疗法或联合疗法时,他们或许能够就肾脏保护提供建议。肿瘤学家和肾病学家之间的合作对于优化患者管理至关重要。本文回顾了癌症与肾脏疾病之间的关系,并探讨了可能影响肾功能的治疗方法。还讨论了监测肾功能的注意事项。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bdaa/5439998/a26cdbf2f2e5/cmar-9-167Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bdaa/5439998/a26cdbf2f2e5/cmar-9-167Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bdaa/5439998/a26cdbf2f2e5/cmar-9-167Fig1.jpg

相似文献

1
Considering renal risk while managing cancer.在管理癌症时考虑肾脏风险。
Cancer Manag Res. 2017 May 16;9:167-178. doi: 10.2147/CMAR.S125864. eCollection 2017.
2
The link between kidney disease and cancer: complications and treatment.肾病与癌症之间的联系:并发症与治疗。
Lancet. 2020 Jul 25;396(10246):277-287. doi: 10.1016/S0140-6736(20)30540-7.
3
Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer.儿童癌症潜在肾毒性治疗后的早期和晚期肾脏不良反应。
Cochrane Database Syst Rev. 2013 Oct 8(10):CD008944. doi: 10.1002/14651858.CD008944.pub2.
4
Importance of monitoring renal function in patients with cancer.监测癌症患者肾功能的重要性。
Cancer Treat Rev. 2012 May;38(3):235-40. doi: 10.1016/j.ctrv.2011.05.001. Epub 2011 May 24.
5
Nephrotoxicity in cancer treatment: An update.癌症治疗中的肾毒性:最新进展。
Adv Cancer Res. 2022;155:77-129. doi: 10.1016/bs.acr.2022.03.005. Epub 2022 Apr 26.
6
Renal cell carcinoma for the nephrologist.肾细胞癌:肾科医师的关注点
Kidney Int. 2018 Sep;94(3):471-483. doi: 10.1016/j.kint.2018.01.023. Epub 2018 Apr 14.
7
Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States.美国实体瘤骨转移患者中肾功能损害的患病率及肾毒性药物的使用情况。
Cancer Med. 2015 May;4(5):713-20. doi: 10.1002/cam4.403. Epub 2015 Feb 8.
8
Renal Function Assessment During Peptide Receptor Radionuclide Therapy.肽受体放射性核素治疗期间的肾功能评估
Semin Nucl Med. 2016 Sep;46(5):462-78. doi: 10.1053/j.semnuclmed.2016.04.006.
9
Bisphosphonates for breast cancer.用于乳腺癌的双膦酸盐类药物。
Cochrane Database Syst Rev. 2005 Jul 20(3):CD003474. doi: 10.1002/14651858.CD003474.pub2.
10
Management of nephrotoxicity of chemotherapy and targeted agents: 2020.化疗和靶向药物肾毒性的管理:2020年
Am J Cancer Res. 2020 Dec 1;10(12):4151-4164. eCollection 2020.

引用本文的文献

1
SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023).SEOM 临床指南:静脉血栓栓塞症(VTE)和癌症(2023 年)。
Clin Transl Oncol. 2024 Nov;26(11):2877-2901. doi: 10.1007/s12094-024-03605-2. Epub 2024 Aug 7.
2
Unveiling the Dichotomy of Urinary Proteins: Diagnostic Insights into Breast and Prostate Cancer and Their Roles.揭示尿液蛋白质的二分法:对乳腺癌和前列腺癌的诊断见解及其作用
Proteomes. 2023 Dec 26;12(1):1. doi: 10.3390/proteomes12010001.
3
Risk factors for early onset acute kidney injury after allogeneic haematopoietic stem cell transplantation and the role of drug-drug interactions.

本文引用的文献

1
A case of melphalan sustained accumulation in an 80-year old patient.一例80岁患者中马法兰持续蓄积的病例。
Int J Clin Pharm. 2015 Dec;37(6):984-7. doi: 10.1007/s11096-015-0197-x. Epub 2015 Sep 22.
2
Tumor lysis syndrome: A clinical review.肿瘤溶解综合征:临床综述
World J Crit Care Med. 2015 May 4;4(2):130-8. doi: 10.5492/wjccm.v4.i2.130.
3
Nephrotoxicity of recent anti-cancer agents.近期抗癌药物的肾毒性
异基因造血干细胞移植后早期急性肾损伤的危险因素及药物相互作用的作用。
Eur J Hosp Pharm. 2024 Oct 25;31(6):498-504. doi: 10.1136/ejhpharm-2023-003703.
4
HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study.RC48 单药或联合免疫治疗局部晚期或转移性尿路上皮癌的多中心真实世界研究:HER2 靶向抗体偶联药物。
Cancer Immunol Immunother. 2023 Jul;72(7):2309-2318. doi: 10.1007/s00262-023-03419-1. Epub 2023 Mar 10.
5
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment.一项评估 Lorlatinib 在轻度、中度和重度肾功能损害的成年人中的药代动力学和安全性的 I 期研究。
Eur J Drug Metab Pharmacokinet. 2022 Mar;47(2):235-245. doi: 10.1007/s13318-021-00747-4. Epub 2022 Jan 11.
6
Enhancing reasoning through reduction of vagueness using fuzzy OWL-2 for representation of breast cancer ontologies.使用模糊OWL-2减少模糊性以增强推理,用于乳腺癌本体的表示。
Neural Comput Appl. 2022;34(4):3053-3078. doi: 10.1007/s00521-021-06517-2. Epub 2021 Oct 8.
7
Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib.达拉非尼联合曲美替尼治疗患者的急性肾损伤的临床特征。
Nephrol Dial Transplant. 2022 Feb 25;37(3):507-514. doi: 10.1093/ndt/gfaa372.
8
Renal and Cardiovascular Toxicities by New Systemic Treatments for Prostate Cancer.前列腺癌新系统治疗的肾脏和心血管毒性
Cancers (Basel). 2020 Jul 1;12(7):1750. doi: 10.3390/cancers12071750.
9
Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.奥拉帕利在晚期实体瘤和肾功能损害患者中的药代动力学和安全性。
Clin Pharmacokinet. 2019 Sep;58(9):1165-1174. doi: 10.1007/s40262-019-00754-4.
Clin Kidney J. 2014 Feb;7(1):11-22. doi: 10.1093/ckj/sft135. Epub 2013 Nov 26.
4
Uric acid and the prediction models of tumor lysis syndrome in AML.尿酸与急性髓系白血病肿瘤溶解综合征的预测模型
PLoS One. 2015 Mar 16;10(3):e0119497. doi: 10.1371/journal.pone.0119497. eCollection 2015.
5
Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States.美国实体瘤骨转移患者中肾功能损害的患病率及肾毒性药物的使用情况。
Cancer Med. 2015 May;4(5):713-20. doi: 10.1002/cam4.403. Epub 2015 Feb 8.
6
Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996-2009.1996 - 2009年美国接受血液透析的医疗保险终末期肾病患者的癌症发病率。
Am J Kidney Dis. 2015 May;65(5):763-72. doi: 10.1053/j.ajkd.2014.12.013. Epub 2015 Feb 7.
7
Update on inflammation in chronic kidney disease.慢性肾脏病炎症研究进展
Blood Purif. 2015;39(1-3):84-92. doi: 10.1159/000368940. Epub 2015 Jan 20.
8
Physicians' preferences for bone metastases drug therapy in the United States.美国医生对骨转移药物治疗的偏好。
Value Health. 2015 Jan;18(1):78-83. doi: 10.1016/j.jval.2014.10.004.
9
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.国际骨髓瘤工作组更新了多发性骨髓瘤的诊断标准。
Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26.
10
Incidence and risk of proteinuria with aflibercept in cancer patients: a meta-analysis.阿柏西普治疗癌症患者时蛋白尿的发生率及风险:一项荟萃分析。
PLoS One. 2014 Nov 3;9(11):e111839. doi: 10.1371/journal.pone.0111839. eCollection 2014.